Retatrutide 2mg — Vial Spec, Reconstitution Math & COA

Lyophilized Retatrutide 2mg Specifications and Physical Characteristics

Retatrutide (LY3437943) is a 39-amino-acid synthetic peptide engineered as a unimolecular triple agonist targeting the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG) receptors. Supplied in a sealed 2mg glass vial, the compound appears as a dense, white-to-off-white lyophilized cake or powder. The lyophilization process utilizes vacuum sublimation under strict aseptic conditions to preserve the structural integrity of the secondary peptide conformation and its C18 fatty diacid moiety, which is conjugated to the lysine residue at position 17 via a gamma-glutamyl linker.

The 2mg fill mass is optimized for short-course bench studies or initial screening assays. Every vial is vacuum-sealed with a chlorobutyl rubber stopper and an aluminum flip-off cap to eliminate moisture ingress, oxygen exposure, and environmental contamination. When handling the 2mg format, researchers must account for both the active peptide content and any inert buffering matrix utilized to stabilize the cake during the freezing cycle. For complete details on our manufacturing standards and available compound offerings, explore our complete catalog of research peptides.

PX1 Research Catalog Availability & Alternative Format Selection

PX1 Research maintains rigorous inventory standards to support academic, government, and institutional laboratories across North America. While this technical guide outlines the specific math and handling for a 2mg vial, please note that PX1 Research regularly adjusts its primary catalog configurations based on research demand and batch synthesis runs. If the exact 2mg vial size is temporarily unlisted or out of stock, laboratories can access our primary catalog listings, such as the Retatrutide research peptide, which may be stocked in alternative mass units like 5mg or 10mg vials.

When switching between vial sizes (e.g., from 2mg to 5mg or 10mg), the molecular structure, purity thresholds, and receptor affinities remain identical. However, volumetric reconstitution parameters must be adjusted proportionally to maintain target working concentrations. Investigators conducting high-throughput screening or extended longitudinal animal trials often prefer larger vial sizes to reduce cost-per-milligram and minimize intra-assay batch variations, whereas smaller 2mg units are ideal for validating assay protocols without wasting excess reconstituted material.

Biochemical Structure and Preclinical Mechanism of Action

Preclinical data indicate that retatrutide exhibits potent, balanced agonism across all three target metabolic receptors, though its relative potency varies by receptor class. Structural modifications derived from the native GIP peptide sequence give retatrutide enhanced stability against enzymatic degradation by dipeptidyl peptidase-4 (DPP-4). In vitro radioperfusion and cell-based reporter assays demonstrate potent activation of human GIP, GLP-1, and glucagon receptors, with EC50 values reflecting high affinity across all three pathways.

In animal models, including rodent metabolic disease models and non-human primates, activation of the GIP and GLP-1 pathways enhances glucose-dependent insulin secretion and suppresses glucagon release during hyper-glycemic states. Concurrently, activation of the glucagon receptor pathway stimulates energy expenditure, alters hepatic lipid metabolism, and promotes lipolysis. Researchers investigating multi-pathway metabolic signaling can reference expanded cross-target literature in our dedicated research library.

Reconstitution Mathematics for 2mg Retatrutide Vials

Accurate reconstitution is vital for maintaining reproducible concentrations across in vitro well plates or in vivo dosing vehicles. To reconstitute a 2mg (2,000 micrograms) vial, a sterile diluent—typically Bacteriostatic Water (0.9% benzyl alcohol) or Phosphate-Buffered Saline (PBS, pH 7.4)—is injected slowly down the inner glass wall of the vial. The total mass of active compound remains constant at 2,000 mcg, while the final liquid volume dictates the concentration per microliter (µL) or milliliter (mL).

To quickly verify your volumetric math and calculate custom concentration outputs for specialized lab equipment, you can utilize our interactive reconstitution calculator. Below are the standard volumetric dilutions for a 2mg vial:

• **1.0 mL Diluent Addition:** Yields a final concentration of 2.0 mg/mL (2,000 mcg/mL). Every 10 µL of solution contains exactly 20 mcg of retatrutide. • **2.0 mL Diluent Addition:** Yields a final concentration of 1.0 mg/mL (1,000 mcg/mL). Every 10 µL of solution contains exactly 10 mcg of retatrutide. • **3.0 mL Diluent Addition:** Yields a final concentration of 0.667 mg/mL (666.7 mcg/mL). Every 10 µL of solution contains approximately 6.67 mcg of retatrutide.

When injecting diluent, never spray fluid directly onto the lyophilized cake to prevent shear stress and physical denaturing of the peptide structure. Allow the solvent to gently wet the powder, then roll the vial slowly between your palms until complete dissolution occurs. Never shake the vial.

Aliquot Planning and Micro-Assay Concentration Management

Because reconstituted peptides are subject to accelerated degradation when exposed to repeated freeze-thaw cycles, sub-aliquoting the working solution immediately after reconstitution is strongly recommended. For cell culture experiments requiring micro-molar or nano-molar working solutions, primary stock aliquots should be prepared in low-protein-binding microcentrifuge tubes.

For instance, if a 2mg vial is reconstituted with 2.0 mL of sterile vehicle to create a 1.0 mg/mL (1,000 µg/mL) master stock, the solution can be aliquoted into twenty 100 µL micro-tubes (each containing 100 µg of retatrutide). Working aliquots intended for immediate use within 48 to 72 hours should be stored at 2°C to 8°C, while long-term stock aliquots should be snap-frozen in liquid nitrogen or dry ice and transferred to a -80°C freezer. Avoid standard manual-defrost freezers, as temperature fluctuations during defrost cycles compromise peptide stability over time.

Analytical Quality Control: HPLC, Mass Spectrometry & COA Verification

PX1 Research enforces stringent quality control protocols for every synthesis lot. Prior to packaging and release, every batch undergoes double-tier analytical testing at an independent ISO 17025-accredited testing laboratory located within the United States. High-Performance Liquid Chromatography (HPLC) is performed to verify peptide purity, ensuring that active retatrutide accounts for ≥99.0% of the total chromatographic peak area, with single impurities restricted to strictly defined limits.

Simultaneously, Electrospray Ionization Mass Spectrometry (ESI-MS) confirms the precise molecular weight of the peptide chain, validating correct sequence assembly and linker conjugation. Every shipment is linked to a lot-specific report; investigators can easily review or download the lot-specific certificate of analysis prior to assay initiation. Furthermore, kinetic chromogenic LAL assays are conducted on every production batch to guarantee that bacterial endotoxin levels remain well below <0.5 EU/mg, preventing confounding inflammatory responses in sensitive cell lines or animal assays.

Comparative Analysis: Retatrutide vs. Dual and Single Agonist Peptides

Understanding how retatrutide compares to single and dual-receptor metabolic peptides is critical when selecting compounds for comparative receptor dynamics or metabolic signaling studies. While single-agonist peptides target a single pathway and dual-agonists engage two complementary pathways, triple-agonists recruit three distinct endocrine signaling axes simultaneously.

In preclinical literature, single GLP-1 receptor agonists such as semaglutide primarily modulate glucose homeostatic pathways and gastric motility. Dual GIP/GLP-1 receptor agonists like tirzepatide demonstrate additive effects on insulin secretion and central satiety signals. Retatrutide extends this pharmacology by integrating glucagon receptor activation alongside GIP and GLP-1 pathways, providing researchers with a unique tool to evaluate elevated energy expenditure and lipid clearance in parallel with glycemic control. Institutional buyers interested in sourcing these related compounds for head-to-head laboratory models can apply for a bulk wholesale bulk account to streamline procurement.

Storage Protocols and Degradation Dynamics

To maintain chemical stability and inhibit peptide hydrolytic cleavage or aggregation, lyophilized retatrutide 2mg vials should be stored at -20°C upon arrival for medium-term storage (up to 12 months) or at -80°C for long-term storage (up to 24 months). Protect the product from direct light exposure by storing vials inside sealed, opaque laboratory boxes.

Once reconstituted with bacteriostatic water containing 0.9% benzyl alcohol, the liquid solution remains stable at 2°C to 8°C for up to 28 days. If reconstituted with unpreserved sterile saline or pure sterile water, the solution must be used within 24 hours to avoid microbial proliferation or rapid degradation. Exposure to room temperature (>25°C) for extended periods accelerates deamidation and oxidation, particularly at the methionine and tryptophan residues within the peptide chain.

Sourcing, Compliance, and Facility Standards

PX1 Research operates strictly within GMP-compliant synthesis facilities within the USA. Every peptide lot is synthesized using solid-phase peptide synthesis (SPPS) technology, followed by reverse-phase HPLC purification and specialized lyophilization. All materials ship directly from our dual logistics hubs located in California and Arizona, enabling same-day dispatch for orders placed Monday through Friday prior to cutoff times.

Our compounds are strictly designated for laboratory research use only by qualified scientific professionals. They are explicitly not intended for human or veterinary administration, medical diagnostic procedures, therapeutic treatment, or clinical use. Compliance documentation and analytical data packages accompany all institutional purchases to ensure full audit readiness.